The Axcellant team recently traveled to New York to meet with research partners and clinical collaborators from across the U.S.
The visit included working sessions focused on upcoming trials and regulatory planning, as well as our AI-powered medical device project for the early detection of congenital heart defects. These conversations are helping shape the next steps in our clinical development roadmap.
We also continued preparations for opening our new U.S. office — a move that will strengthen our ability to work closely with sponsors and research teams in North America.
Beyond the meetings, the trip offered space for team reflection and strategic thinking — sometimes the best ideas come outside of meeting rooms.
Thank you to everyone who took the time to meet with us. We look forward to continuing the conversations and turning shared plans into action.
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
The FDA and the European Commission are changing the rules of the game simultaneously. The shift is from a single…
Modern nuclear medicine is a high-tech discipline that requires advanced facilities, infrastructure, qualified staff, and know-how. The reliable supply of radionuclides,…
Copyright @ 2026 Axcellant